A detailed history of Met Life Investment Management, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 37,332 shares of CLDX stock, worth $887,754. This represents 0.01% of its overall portfolio holdings.

Number of Shares
37,332
Previous 37,332 -0.0%
Holding current value
$887,754
Previous $1.38 Million 8.18%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$32.76 - $42.56 $182,407 - $236,974
5,568 Added 17.53%
37,332 $1.38 Million
Q1 2024

May 14, 2024

BUY
$35.22 - $51.88 $1.12 Million - $1.65 Million
31,764 New
31,764 $1.33 Million
Q3 2023

May 09, 2024

BUY
$25.45 - $37.46 $8,882 - $13,073
349 Added 1.47%
24,073 $662,000
Q2 2023

Apr 29, 2024

BUY
$30.29 - $38.28 $729,171 - $921,514
24,073 New
24,073 $816,000
Q2 2023

Aug 10, 2023

BUY
$30.29 - $38.28 $10,571 - $13,359
349 Added 1.47%
24,073 $816,000
Q1 2023

May 09, 2024

BUY
$34.78 - $47.43 $825,120 - $1.13 Million
23,724 New
23,724 $854 Million
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $31,336 - $42,734
-901 Reduced 3.66%
23,724 $853,000
Q4 2022

May 10, 2024

SELL
$27.78 - $45.38 $16,195 - $26,456
-583 Reduced 2.31%
24,625 $1.1 Million
Q4 2022

Jun 14, 2023

BUY
$27.78 - $45.38 $25,029 - $40,887
901 Added 3.8%
24,625 $1.1 Million
Q4 2022

Mar 22, 2023

SELL
$27.78 - $45.38 $16,195 - $26,456
-583 Reduced 2.31%
24,625 $1.1 Million
Q4 2022

Feb 15, 2023

SELL
$27.78 - $45.38 $16,195 - $26,456
-583 Reduced 2.31%
24,625 $1.1 Million
Q3 2022

Jun 14, 2023

BUY
$22.7 - $37.57 $33,686 - $55,753
1,484 Added 6.26%
25,208 $708,000
Q2 2022

Jun 20, 2023

BUY
$20.5 - $37.33 $30,422 - $55,397
1,484 Added 6.26%
25,208 $679,000
Q1 2022

May 10, 2024

BUY
$27.64 - $39.32 $696,749 - $991,178
25,208 New
25,208 $858,000
Q1 2022

Jun 20, 2023

BUY
$27.64 - $39.32 $41,017 - $58,350
1,484 Added 6.26%
25,208 $858,000
Q1 2022

Mar 22, 2023

BUY
$27.64 - $39.32 $252,961 - $359,856
9,152 Added 57.0%
25,208 $858,000
Q1 2022

May 12, 2022

BUY
$27.64 - $39.32 $252,961 - $359,856
9,152 Added 57.0%
25,208 $859,000
Q4 2021

Jun 21, 2023

SELL
$35.68 - $56.27 $273,594 - $431,478
-7,668 Reduced 32.32%
16,056 $620,000
Q3 2021

May 17, 2024

BUY
$28.95 - $55.99 $44,843 - $86,728
1,549 Added 10.68%
16,056 $866,000
Q3 2021

Jun 21, 2023

SELL
$28.95 - $55.99 $221,988 - $429,331
-7,668 Reduced 32.32%
16,056 $866,000
Q3 2021

Mar 22, 2023

BUY
$28.95 - $55.99 $44,843 - $86,728
1,549 Added 10.68%
16,056 $866,000
Q3 2021

Nov 15, 2021

BUY
$28.95 - $55.99 $44,843 - $86,728
1,549 Added 10.68%
16,056 $867,000
Q2 2021

May 17, 2024

SELL
$20.71 - $35.37 $357,392 - $610,380
-17,257 Reduced 54.33%
14,507 $485,000
Q2 2021

Jun 21, 2023

SELL
$20.71 - $35.37 $190,884 - $326,005
-9,217 Reduced 38.85%
14,507 $485,000
Q2 2021

Mar 22, 2023

SELL
$20.71 - $35.37 $209,543 - $357,873
-10,118 Reduced 41.09%
14,507 $485,000
Q2 2021

Aug 16, 2021

BUY
$20.71 - $35.37 $300,439 - $513,112
14,507 New
14,507 $485,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.11B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.